Palivizumab

INDICATIONS

FDA

  • Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease (bronchopulmonary dysplasia, premature birth, and hemodynamically significant congenital heart disease).

NON-FDA APPROVED USES

  • Treatment of severe RSV pneumonia in immunocompromised adult patients (limited data).

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: November 9, 2022